Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III booster study of Hib-MenC versus Infanrix Hexa in 14-month-old children
2004-001249-14Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2004
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Hib-MenC-TT and pertussis filamentous haemagglutinin in Haemophilus influenzae type b disease (Hib) and meningococcal group C disease (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity one month after booster vaccination and Safety and reactogenicity. Started Sep 2004; status: completed.
02
Drugs
Hib-MenC-TTpertussis filamentous haemagglutinin
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C disease
Beyond the preview
Go deeper on 2004-001249-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001249-14.